Cobolimab: Acceptance of regulatory submissions in US/EU (based on COSTAR trial) for 2L NSCLC in H2 2025 (GSK) - Feb 5, 2025 - Q4 & FY2024 Results: Regulatory decisions in US/EU (based on COSTAR trial) for 2L NSCLC in 2026
EMA approval • EMA filing • FDA approval • FDA filing • Lung Cancer • Non Small Cell Lung Cancer • Oncology
|